Technology

CTI BioPharma

$3.12
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-1.58%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell CTI BioPharma and other stocks, options, and ETFs commission-free!

About CTIC

CTI BioPharma Corp. (DE) Common Stock, also called CTI BioPharma, is a biopharmaceutical company, which focuses on the development, acquisition and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. The listed name for CTIC is CTI BioPharma Corp. (DE) Common Stock.

CEO
Adam R. Craig
Employees
25
Headquarters
Seattle, Washington
Founded
1991
Market Cap
235.47M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
476.51K
High Today
$3.20
Low Today
$3.11
Open Price
$3.17
Volume
724.21K
52 Week High
$4.03
52 Week Low
$0.62

Collections

CTIC Earnings

-$0.20
-$0.13
-$0.07
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, After Hours

You May Also Like

ROKT
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure